Therapeutic Targeting of the Proteasome in Disease

In honor of Julian Adams, Ph.D., Kenneth C. Anderson M.D., Alfred L. Goldberg, Ph.D. , and Paul G. Richardson, M.D. for their discovery, preclinical and clinical development of Bortezomib (Velcade) to FDA approval and front line therapy for the treatment of patients with multiple myeloma.

Julian Adams

Julian Adams | 2012 Recipient

For the discovery, preclinical and clinical development of  bortezomib to FDA approval and front line therapy for the treatment of patients with multiple myeloma.

Julian Adams, PhD is President of Research and Development at Infinity Pharmaceuticals. Adams is responsible for the full spectrum of Infinity’s drug discovery, preclinical, and clinical development strategy, and regulatory affairs activities. Prior to joining Infinity in 2003, he was the Senior Vice President of Drug Discovery and Development at Millennium Pharmaceuticals. In this capacity he had global responsibility for multiple drug discovery programs, including the successful discovery and development of Velcade® (bortezomib), a proteasome inhibitor for cancer therapy. He joined Millennium through its acquisition of LeukoSite in 1999 where he was Senior Vice President of Research and Development. Adams joined LeukoSite as a result of its acquisition of ProScript, Inc., where he had served as a member of the founding management team, Executive Vice President of Research and Development, and a member of the Board of Directors. Earlier in his career, Adams served in various positions, including Director of Medicinal Chemistry at Boehringer Ingelheim, where he successfully discovered the drug Viramune® (nevirapine) for HIV. Also, from 1982–
1987, he was a medicinal chemist at Merck.

Adams has received many awards, including the 2001 Ribbon of Hope Award for Velcade® from the International Myeloma Foundation. He is an inventor of more than 40 patents and has authored over 100 papers and book chapters in peer reviewed journals. He is the editor of Proteasome Inhibition in Cancer Therapy, published in July 2004.

Adams received his BS from McGill University and his PhD from the Massachusetts Institute of Technology in the field of synthetic organic chemistry.

Opening Remarks

Jeffrey S. Flier, MD

Dean of the Faculty of Medicine, Harvard University

Joan S. Brugge, PhD

Louise Foote Pfeiffer Professor of Cell Biology and Chair of the Department of Cell Biology, Harvard Medical School

Alfred L. Goldberg, PhD

Professor of Cell Biology, Harvard Medical School Functions of the Proteasome: From Protein Degradation to Drug Development

Julian Adams, PhD

President, Research and Development, Infinity Pharmaceuticals The Discovery and Development of Bortezomib

Kenneth C. Anderson, MD

Kraft Family Professor of Medicine, Harvard Medical School, Director of the LeBow Institute for Myeloma Therapeutics and Director of the Jerome Lipper Multiple Myeloma Center, Dana-Farber Cancer Institute Bench to Bedside Translation of Proteasome Inhibitor Therapy in Multiple Myeloma

Paul G. Richardson, MD

Associate Professor of Medicine, Harvard Medical School and Clinical Director of the Jerome Lipper Multiple Myeloma Center, Dana-Farber Cancer Institute The Clinical Development of Bortezomib in Multiple Myeloma: from Single Agent to Combinations and Beyond

Sign up to receive updates

Sign up to receive updates

Past Symposia

For questions about the prize, please contact us.

Contact Us
I am very grateful to the Warren Alpert Foundation for recognizing my work, and I am honored to be in the company of the previous award winners.
- Robert Langer

Robert Langer | 2011 Recipient

In recognition of their application of bioengineering principles to fundamental improvements in human health.

Robert S. Langer Jr., ScD is the David H. Koch Institute Professor at the Massachusetts Institute of Technology. He is also a faculty member of the Harvard-MIT Division of Health Sciences and Technology and the David H. Koch Institute for Integrative Cancer Research. He re¬ceived his Bachelor’s degree from Cornell University in 1970 and his ScD from the Massachusetts Institute of Technology in 1974, both in Chemical Engineering. From 1974–1977 he worked as a postdoctoral fellow for cancer researcher Judah Folkman at the Children’s Hospital Boston and at Harvard Medical School.

Langer holds more than 800 granted or pending patents. He has also authored more than 1,130 scientific papers and has participated in the founding of multiple technology companies. He has received numerous awards, including the National Medal of Science, the 10th Annual Heinz Award in the category of Technology, the Economy and Employment, the Charles Stark Draper Prize, the Lemelson-MIT Prize, the Albany Medical Center Prize in Medicine and Biomedical Research, the Millennium Technology Prize in 2008, and the American Chemical Society Priestley Medal in 2012. At 43, Langer is the youngest person in history to be elected to all three American science academies: the National Academy of Sciences, the National Academy of Engineering, and the Institute of Medicine.

Langer’s work is at the interface of biotechnology and materials science. Langer and the researchers in his lab focus on the study and development of polymers to deliver drugs––particularly genetically engineered proteins, DNA, and RNAi––continuously at controlled rates for prolonged periods of time.

 View Past Recipients